# Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

Source: https://onco.cc/trials/nct03600441/  
OnCo record `nct03600441` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abexinostat in follicular lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT03600441 by Xynomic Pharmaceuticals, Inc., with 139 participants planned, started 2018-08-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Abexinostat. Conditions listed: Follicular Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03600441
- Phase: 2
- Setting: Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
- Sponsor: Xynomic Pharmaceuticals, Inc.
- Enrolled: 139

## Sources

- ClinicalTrials.gov NCT03600441: https://clinicaltrials.gov/study/NCT03600441

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Abexinostat](https://onco.cc/drugs/abexinostat/)

---
JSON: https://onco.cc/api/v1/entities/nct03600441.json